My watch list
my.chemeurope.com  
Login  

Pristinamycin



Pristinamycin
Systematic (IUPAC) name
 ?
Identifiers
CAS number  ?
ATC code J01FG01
PubChem  ?
Chemical data
Formula  ?
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Pristinamycin (INN), also spelled pristinamycine, is an antibiotic used primarily in the treatment of staphylococcal infections, and to a lesser extent streptococcal infections. It is a streptogramin group antibiotic, similar to virginiamycin, derived from the bacterium Streptomyces pristina spiralis. It is marketed in Europe by Sanofi-Aventis under the trade name Pyostacine.

Additional recommended knowledge

Pristinamycin is a mixture of two components that have a synergistic antibacterial action. Pristinamycin I is a macrolide, and results in pristinamycin having a similar spectrum of action to erythromycin. Pristinamycin II is a depsipeptide.[1]

Clinical use

Despite the macrolide component, it is effective against erythromycin-resistant staphylococci and strepcococci.[2][3] Importantly, it is active against methicillin-resistant Staphylococcus aureus (MRSA). Its usefulness for severe infections, however, may be limited by the lack of an intravenous formulation owing to its poor solubility.[4] Nevertheless it is sometimes used as an alternative to rifampicin+fusidic acid or linezolid for the treatment of MRSA.

The lack of an intravenous formulation led to the development of the pristinamycin-derivative quinupristin/dalfopristin, which may be administered intravenously for more severe MRSA infections.

See also

 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pristinamycin". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE